Is this email not displaying correctly?
View it in your browser.
Newswise - News for Journalists

Newswise Special Wire
Tuesday, February 24, 2015

Public edition | newswise.com

Newswise Cancer Research Wire for 24-Feb-2015
FacebookTwitterLinkedInStumbleupon

Cancer Research Wire

Cancer research news for the public and news media. More stories can be found at the Newswise Cancer News Source.

Gene Variant and Risk and Severity of Nerve Disorder Linked to Cancer Drug

Children with acute lymphoblastic leukemia who had a certain gene variant experienced a higher incidence and severity of peripheral neuropathy after receiving treatment with the cancer drug vincristine, according to a study in the February 24 issue of JAMA.

(Embargo expired on 24-Feb-2015 at 11:00 ET)

JAMA

– JAMA - Journal of the American Medical Association

Decline in Smoking Rates May Increase Lung Cancer Mortality Due to Inadequate Screening Guidelines

A decline in smoking rates may mean that many people who could have benefited from early detection of lung cancer are dying because they don’t qualify for low-dose CT scans, according to a group of Mayo Clinic researchers. Their research appears in the Feb. 24 issue of JAMA, the journal of the American Medical Association.

(Embargo expired on 24-Feb-2015 at 11:00 ET)

JAMA

– Mayo Clinic

Inherited Gene Variation Leaves Young Leukemia Patients at Risk for Peripheral Neuropathy

Researchers have identified the first genetic variation that is associated with increased risk and severity of peripheral neuropathy following treatment with a widely used anti-cancer drug. Investigators also found evidence of how it may be possible to protect young leukemia patients without jeopardizing cures. St. Jude Children’s Research Hospital scientists led the study, which appears today in the Journal of the American Medical Association.

 • Image(s) embedded • 

JAMA; CA36401; GM92666; GM61393; CA136765; CA165823; CA21765; CA98543; CA98413; CA114766

– St. Jude Children's Research Hospital

In Triple-Negative Breast Cancer, Even Low-Androgen Tumors Respond to Anti-Androgen Therapy

Clinical trials are underway of anti-androgen drugs against high-androgen triple-negative breast cancers, and new work from the University of Colorado Cancer Center shows the threshold for benefit from anti-androgen therapies may be much lower than previously thought: even breast cancers with few androgen receptors benefit from anti-androgen therapy.

 • Image(s) embedded • 

Molecular Cancer Therapeutics; DOD BCRP Clinical Translational Award BC120183

– University of Colorado Cancer Center

Rutgers Cancer Institute of New Jersey Advances Understanding of Surgical Treatment Options for Genitourinary Cancers

Helping to advance scientific and clinical knowledge to combat cancers that affect the bladder, kidneys, urinary tract and male reproductive organs, physician scientists at Rutgers Cancer Institute of New Jersey are presenting their latest research in this area at the 2015 Genitourinary Cancers Symposium. At focus are studies examining radical cystectomies and patients with uncontrolled diabetes and a look at how laparoscopic and robotic surgeries have evolved in adrenal cancers.

 • Image(s) embedded •  (Embargo expired on 23-Feb-2015 at 17:00 ET)

Genitourinary Cancers Symposium, Feb-2015

– Rutgers Cancer Institute of New Jersey

MD Anderson Studies Skin Cancer Patients Resistant to Leading Therapy

Powerful drugs known as BRAF-inhibitors have been crucial for melanoma patients, saving lives through their ability to turn off the BRAF protein’s power to spur cancer cell growth.

 • Image(s) embedded •  (Embargo expired on 23-Feb-2015 at 17:00 ET)

Journal of Clinical Investigation (JCI)

– University of Texas M. D. Anderson Cancer Center

Physicians Performing Breast Exams May Miss Masses Deep in Breast

Many physicians who tested their breast-examination skills on a new type of pressure-sensing breast model failed to detect masses deep in the breast because they were not pressing hard enough, according to a study published in the New England Journal of Medicine.

New England Journal of Medicine

– Loyola University Health System

Penn Medicine Physician Finds No Preventive Benefits for Widely Used Kidney Cancer Drugs

Two widely used targeted therapy drugs— approved by the FDA for use in metastatic kidney cancer —are no more effective than a placebo in preventing return of the disease to increase life spans of patients suffering from advanced kidney cancer after surgery, according to new results to be presented by a researcher at the University of Pennsylvania’s Abramson Cancer Center during the 2015 Genitourinary Cancers Symposium.

2015 Genitourinary Cancers Symposium

– Perelman School of Medicine at the University of Pennsylvania

Master Gene Regulatory Pathway Revealed as Key Target for Therapy of Aggressive Pediatric Brain Cancer

Working with cells taken from children with a very rare but ferocious form of brain cancer, Johns Hopkins Kimmel Cancer Center scientists have identified a genetic pathway that acts as a master regulator of thousands of other genes and may spur cancer cell growth and resistance to anticancer treatment.

Oncotarget; P30 CA006973; CA91048; 46274

– Johns Hopkins Medicine

Disparities in Breast Cancer Care Linked to Net Worth

Household net worth is a major and overlooked factor in adherence to hormonal therapy among breast cancer patients and partially explains racial disparities in quality of care.

 • Image(s) embedded • 

Journal of Clinical Oncology; RSGT-11-012-01-CPHPS; R25 CA094061),

– Columbia University Medical Center

Adjuvant Sorafenib and Sunitinib Do Not Improve Outcomes in Locally Advanced Kidney Cancer

Findings from a federally funded study suggest that patients with locally advanced kidney cancer should not be treated with either adjuvant (post-surgery) sorafenib or sunitinib. The average period to disease recurrence was similar between those who received sorafenib or sunitinib after surgery (5.6 years) and those treated with placebo (5.7 years). The study will be presented at the upcoming 2015 Genitourinary Cancers Symposium in Orlando.

2015 Genitourinary Cancers Symposium

– American Society of Clinical Oncology (ASCO)

Active Surveillance of Intermediate-Risk Prostate Cancer Associated With Decreased Survival

An analysis of data on 945 patients with prostate cancer that is managed with active surveillance shows differences in outcomes depending on whether the patient was low or intermediate risk at diagnosis. Compared to patients with low-risk disease, those with intermediate-risk cancer (PSA >10ng/ml or Gleason score 7 or clinical stage T2b/2c) had a nearly four-fold higher chance of dying from prostate cancer within 15 years. The study will be presented at the upcoming 2015 Genitourinary Cancers Symposium in Orlando.

2015 Genitourinary Cancers Symposium

– American Society of Clinical Oncology (ASCO)

Men Who Have Had Testicular Cancer Are More Likely to Develop Prostate Cancer, Although Overall Risk of Developing Aggressive Disease is Low

A case-control study of close to 180,000 men suggests that the incidence of prostate cancer is higher among men with a history of testicular cancer (12.6 percent) than among those without a history of testicular cancer (2.8 percent). Men who have had testicular cancer were also more likely to develop intermediate- or high-risk prostate cancers. The study will be presented at the upcoming 2015 Genitourinary Cancers Symposium in Orlando.

2015 Genitourinary Cancers Symposium

– American Society of Clinical Oncology (ASCO)

Early Evidence of Increase in Higher-Risk Prostate Cancers From 2011-2013

An analysis of data on roughly 87,500 men treated for prostate cancer since 2005 finds a notable increase in higher-risk cases of the disease between 2011 and 2013. The study will be presented at the upcoming 2015 Genitourinary Cancers Symposium in Orlando.

2015 Genitourinary Cancers Symposium

– American Society of Clinical Oncology (ASCO)

Androgen Receptor Abnormality May Not Be Associated With Primary Resistance to Taxane Chemotherapy

ALEXANDRIA, Va. – Findings from a small prospective study suggest that androgen receptor V7 (or AR-V7) status does not significantly affect response to taxane chemotherapy in men with metastatic castration-resistant prostate cancer (mCRPC). Treatment outcomes were largely similar for the 17 patients with AR-V7-positive prostate cancer and the 20 patients with AR-V7-negative disease included in this analysis. The study will be presented at the upcoming 2015 Genitourinary Cancers Symposium in Orlando.

2015 Genitourinary Cancers Symposium

– American Society of Clinical Oncology (ASCO)

NCCN Publishes New Patient-Friendly Treatment Guidelines for Acute Lymphoblastic Leukemia

NCCN has published NCCN Guidelines for Patients®: Acute Lymphoblastic Leukemia (ALL), the newest addition to the library of NCCN Guidelines for Patients®.

– National Comprehensive Cancer Network® (NCCN®)

Palbociclib Shows Promise in Patients with Hormone-Resistant Breast Cancer, Penn Study Finds

Palbociclib, an investigational oral medication that works by blocking molecules responsible for cancer cell growth, is well tolerated and extends progression-free survival in newly diagnosed, advanced breast cancer patients, including those whose disease has stopped responding to traditional endocrine treatments.

Clinical Cancer Research

– Perelman School of Medicine at the University of Pennsylvania

Researchers Sheds New Light on Biological Pathways of Vestibular Schwannomas

Researchers from the Eaton-Peabody Laboratories of Massachusetts Eye and Ear and the Harvard Medical School/ Massachusetts Institute of Technology Program in Speech and Hearing Bioscience and Technology have revealed new understanding of the pathobiology behind a head and neck tumor that may someday lead to new methods of targeted drug therapy.

 • Image(s) embedded • 

Cancer Biology and Therapy, Feb-2015

– Massachusetts Eye and Ear Infirmary

Breast Cancer Spread May Be Tied to Cells That Regulate Blood Flow

Tumors require blood to emerge and spread. That is why scientists at The University of Texas MD Anderson Cancer Center believe that targeting blood vessel cells known as pericytes may offer a potential new therapeutic approach when combined with vascular growth factors responsible for cell death.

 • Image(s) embedded •  (Embargo expired on 19-Feb-2015 at 12:00 ET)

Cell Reports

– University of Texas M. D. Anderson Cancer Center

Mayo Clinic Researchers Identify Gene that Pushes Normal Pancreas Cells to Change Shape

A research team led by investigators from Mayo Clinic’s campus in Jacksonville, Florida, and the University of Oslo, Norway, have identified a molecule that pushes normal pancreatic cells to transform their shape, laying the groundwork for development of pancreatic cancer — one of the most difficult tumors to treat.

Nature Communications; 08-20-25-STOR; CA135102, GM86435, CA140182; P50CA102701

– Mayo Clinic

New Nanogel for Drug Delivery

MIT chemical engineers have designed a new type of self-healing hydrogel that could be injected through a syringe. Such gels, which can carry one or two drugs at a time, could be useful for treating cancer, macular degeneration, or heart disease, among other diseases, the researchers say.

Nature Communications, Feb-2015

– Koch Institute for Integrative Cancer Research at MIT

New Study by UCLA Researchers Could Lead the Way for Better Assessment of Treatment Options for Men with Prostate Cancer

UCLA researchers have found that radiation therapy is the most common treatment for men with prostate cancer regardless of the aggressiveness of the tumor, risk to the patient and overall patient prognosis. These findings lay the groundwork for improved treatment assessment by physicians and to better inform men fighting the disease.

 • Image(s) embedded • 

JAMA Oncology

– University of California, Los Angeles (UCLA), Health Sciences

Development of Personalized Cellular Therapy for Brain Cancer

Immune cells engineered to seek out and attack a type of deadly brain cancer were found to be both safe and effective at controlling tumor growth in mice that were treated with these modified cells. The results paved the way for a newly opened clinical trial for glioblastoma patients at Penn.

(Embargo expired on 18-Feb-2015 at 14:00 ET)

Science Translational Medicine; DP2CA174502, K08-166039

– Perelman School of Medicine at the University of Pennsylvania

Drug/Chemotherapy Combination Lengthens Survival for Patients with Aggressive Form of Breast Cancer

Treatment combining chemotherapy with two drugs lengthens survival of patients with HER2-positive metastatic breast cancer by an average of nearly 16 months, according to a study led by Sandra M. Swain, MD, medical director, Washington Cancer Institute at MedStar Washington Hospital Center. The results from the CLEOPATRA trial were published today in the New England Journal of Medicine.

 • Image(s) embedded •  (Embargo expired on 18-Feb-2015 at 17:00 ET)

New England Journal of Medicine

– MedStar Washington Hospital Center

MD Anderson Joins CATCH Global Foundation to Boost Child Health, Prevent Cancer in Later Years

Cancer prevention experts at The University of Texas MD Anderson Cancer Center have allied with the CATCH Global Foundation, whose comprehensive child health program reaches children and their families in more than 10,000 educational settings nationwide, to promote behavior that will lower children’s lifelong risk of developing cancer.

(Embargo expired on 18-Feb-2015 at 10:00 ET)
Expert(s) available

– University of Texas M. D. Anderson Cancer Center

A Dog Lives On; Now the Stage Is Being Set for Treating Humans

The National Cancer Institute has awarded Scott Verbridge, an assistant professor of biomedical engineering and mechanics at Virginia Tech, a $386,149 research grant to move a process that has been used in clinical trials a step closer to using on humans. Verbridge will lead a research team focusing on targeting and destroying the most therapy-resistant infiltrative cells in malignant glioma.

 • Image(s) embedded • 

Journal of Technology Cancer Research and Treatment

– Virginia Tech

Popular Soda Ingredient Poses Cancer Risk to Consumers

Public health researchers have analyzed soda consumption data in order to characterize people’s exposure to a potentially carcinogenic byproduct of some types of caramel color. Caramel color is a common ingredient in colas and other dark soft drinks. The results show that between 44 and 58 percent of people over the age of six typically have at least one can of soda per day, possibly more, potentially exposing them to 4-methylimidazole (4-MEI), a possible human carcinogen formed during the manufacture of some kinds of caramel color.

PLOS One

– Johns Hopkins Bloomberg School of Public Health

New HPV Vaccine Shows Promise to Dramatically Reduce Cervical Cancer

Renowned UAB HPV expert, Warner Huh, says new nine-valent HPV vaccine has the potential to eradicate the majority of cervical cancer.

 • Video / Image(s) embedded • 

New England Journal of Medicine

– University of Alabama at Birmingham

Mobile Cancer Survivor Clinic Brings UTSW Expertise to Doorstep of Underserved Cancer Survivors

UT Southwestern’s Moncrief Cancer Institute and Harold C. Simmons Comprehensive Cancer Center debuted the Mobile Cancer Survivor Clinic − a custom, fully equipped 18-wheeler that can deliver follow-up and screening services to cancer survivors.

 • Image(s) embedded • 

– UT Southwestern Medical Center

New Study Reveals How to Improve Chemotherapy Use in Prostate Cancer

Next generation chemotherapy for prostate cancer has unique properties that could make it more effective earlier in treatment if confirmed in clinical trials.

(Embargo expired on 17-Feb-2015 at 00:05 ET)

Clinical Cancer Research

– Thomas Jefferson University

Potential New Breathalyzer for Lung Cancer Screening

Chinese researchers have developed a simple, rapid device for detecting volatile organic compounds on the breath, demonstrating potential for early cancer detection

 • Image(s) embedded •  (Embargo expired on 17-Feb-2015 at 11:00 ET)

Review of Scientific Instruments

– American Institute of Physics (AIP)

Melanoma’s Addiction to Glutamine Is the Basis for Cancer Growth

Researchers find that melanoma cells are dependent on a source of glutamine for growth irrespective of the mutation(s) that drive the cancer.

Oncotarget

– Sanford-Burnham Medical Research Institute

MAGE Genes Provide Insight Into Optimizing Chemotherapy, Cancer Researchers Find

UT Southwestern Medical Center scientists have identified a new biomarker that could help identify patients who are more likely to respond to certain chemotherapies.

 • Image(s) embedded • 

Cell

– UT Southwestern Medical Center

Chromosome "Bumper Repair" Gene Predicts Cancer Patient Outcomes

University of Colorado Cancer Center study published in the journal SCIENCE shows that mRNA levels for the gene TERT predict patient outcomes in bladder cancer, helping doctors and researchers pinpoint most aggressive forms of the disease and choose appropriate treatments.

 • Image(s) embedded • 

Science; NIH CA075115; NIH CA104106; NIH GM08759; NIH GM099705

– University of Colorado Cancer Center

New Cancer Treatments Could Evolve From UTSW Research Showing That Acetate Supplements Speed Up Cancer Growth

UT Southwestern Medical Center researchers seeking novel ways to combat cancer found that giving acetate, a major compound produced in the gut by host bacteria, to mice sped up the growth and metastasis of tumors.

 • Image(s) embedded • 

PLoS ONE

– UT Southwestern Medical Center

Gene Mutation Drives Cartilage Tumor Formation

Duke Medicine researchers have shown how gene mutations may cause common forms of cartilage tumors. In a study published in the Feb. 16, 2015, issue of the Proceedings of the National Academy of Sciences, Duke researchers and their colleagues revealed that mutations in the isocitrate dehydrogenase (IDH) gene contribute to the formation of benign tumors in cartilage that can be a precursor to malignancies.

 • Image(s) embedded •  (Embargo expired on 16-Feb-2015 at 15:00 ET)

PNAS; R01AR066765

– Duke Medicine

Molecule that Provides Cellular Energy Found Key to Aggressive Thyroid Cancer

Cancer researchers at Mayo Clinic’s campus in Jacksonville, Florida, have identified a molecule they say is important to survival of anaplastic thyroid carcinoma (ATC) — a lethal tumor with no effective therapies. The molecule also seems to play a role in a wide range of cancers.

Journal of Clinical Endocrinology and Metabolism

– Mayo Clinic

New Therapeutic Strategy Discovered for Ovarian Cancer

Researchers in the laboratory of Rugang Zhang have discovered a target for ovarian clear cell carcinoma, a very difficult-to-treat form of the disease.

 • Image(s) embedded • 

U.S. Department of Defense Ovarian Cancer Academy Award OC093420 ; Nature Medicine; National Institutes of Health grant R01CA160331 ; National Institutes of Health grant R01CA16337...

– Wistar Institute

Study Identifies Promising Drug Target in Certain Breast and Ovarian Cancers

Study by Dana-Farber Cancer Institute scientists indicates that the pool of patients who can benefit from the drug olaparib is potentially much wider – and offers a ready means of identifying them.

Nature, Feb-2015

– Dana-Farber Cancer Institute

Survivors of Childhood Cancer at Risk for Developing Hormone Deficiencies as Adults

Decades after undergoing cranial irradiation for childhood cancer, St. Jude Children’s Research Hospital investigators found that adult survivors of pediatric cancer remain at risk for pituitary hormone deficiencies that may diminish their health and quality of life. The findings appear in the February 10 edition of the Journal of Clinical Oncology.

– St. Jude Children's Research Hospital

Looking Back on Two Decades of Breast Cancer Treatment: Targeted Therapy and Improved Surgical Procedures are Key Enhancements

NCCN has published the 20th annual edition of the NCCN Guidelines® for Breast Cancer, one of the original NCCN Guidelines published in November 1996.

– National Comprehensive Cancer Network® (NCCN®)

Moffitt Cancer Center Physicians Promote Screening Strategies for Those at High-Risk for Melanoma

Melanoma, the most deadly type of skin cancer, was to blame for approximately 9,700 deaths in 2014. And with the number of melanoma cases increasing each year, it is believed that the disease could become one of the most common types of cancer in the United States by 2030. Promoting and developing national screening strategies may help to reduce deaths due to melanoma. According to Vernon K. Sondak, M.D., chair of the Department of Cutaneous Oncology at Moffitt Cancer Center, “it is time to embrace the opportunity to decrease melanoma mortality through risk-stratified education and screening.”

The Journal of the American Medical Association, Feb-2015

– Moffitt Cancer Center

Study Demonstrates Potentially Faster and More Accurate Mode of Cancer Treatment with New Laser Technology

Surgeons rely on 200-year-old technology when removing cancer--sight and touch--to determine how much to remove and what to leave alone. Laser technology pioneered at Florida Atlantic University has the promise to help a surgeon better determine if an area is cancer or healthy tissue. Moreover, when combined with laser treatment for cancer, this work lays the groundwork for laser robotic treatment of cancer.

 • Image(s) embedded • 

Lasers in Surgery and Medicine

– Florida Atlantic University

Two Cell-Signaling Molecules Found to Suppress the Spread of Melanoma

In what is believed to be the largest epigenetic analysis to date of cell-signaling molecules in early-stage melanoma, researchers at NYU Langone Medical Center and its Laura and Isaac Perlmutter Cancer Center have identified two tiny bits of non-coding genetic material in primary tumors that appear critical to stalling the cancer’s spread -- and essentially setting the biological fate of the disease.

– NYU Langone Medical Center

Bypassing Resistance to PI3K Therapy Paves the Way to Novel Anticancer Strategies

A study led by researchers at The Wistar Institute has shown that targeting both PI3K and the mitochondria within these cancer cells can dramatically improve the effectiveness of targeted therapy and significantly reduce the chances of developing resistance.

 • Image(s) embedded • 

Journal of the National Cancer Institute

– Wistar Institute

Late Melanoma Patients Will Need Several Lines of Therapy, Intralesional Treatment Promising Says New Paper

Despite advances in melanoma treatment, many patients with advanced melanoma will need several lines of therapy according to a recent paper in Current Opinion in Oncology.

 • Image(s) embedded • 

Current Opinion in Oncology

– Provectus Biopharmaceuticals, Inc

Lenvatinib Shows Promise for Patients with Radioiodine-Refractory Thyroid Cancer

In a pivotal Phase III study led by researchers at The University of Texas MD Anderson Cancer Center, the oral anti-angiogenic therapy lenvatinib has shown dramatic improvement in progression-free survival in patients with advanced radioiodine-refractory thyroid cancer.

 • Image(s) embedded •  (Embargo expired on 11-Feb-2015 at 17:00 ET)

New England Journal of Medicine

– University of Texas M. D. Anderson Cancer Center

Researcher Identifies Novel Pathway That Solid Tumor Cancer Cells Activate for Growth

A common, yet previously undistinguished protein, which is elevated in many late-stage cancers, may play a strategic role in tumor growth through a non-conventional pathway, researchers at the Indiana University School of Medicine report.

PNAS; R01 CA172256

– Indiana University

Findings Could Improve Targeted Chemotherapy Drug Delivery

Silicon nanomaterials used for localized delivery of chemotherapy drugs behave differently in cancerous tumors than in healthy tissues. The new findings could help scientists improve materials for the controlled release of the chemotherapy drugs.

Nature Communications, Feb-2015

– American Technion Society

Study: Young Adult Survivors Most Distressed After Leukemia and Lymphoma Treatment

45 percent of younger patients report moderate-to-high distress, whereas only 18 percent of older patients report similarly elevated levels.

Journal of Psychosocial Oncology; NCI 5K07CA108565

– University of Colorado Cancer Center

First-in Man: Tumor Suctioned From Vein of Cancer Patient to Allow Minimally Invasive Kidney Surgery

Physicians at Henry Ford Hospital successfully suctioned a cancerous tumor from a major vein in a patient with metastatic kidney cancer, clearing the way for him to undergo a minimally-invasive kidney removal. This allowed him to participate in a clinical trial using genetic material from his tumor to produce a vaccine to help fight his metastatic disease.

 • Video / Image(s) embedded • 

– Henry Ford Health System

The Medical Minute: Clearing the Confusion Around Cancer Causes

Lots of things have been associated with higher risks of developing certain cancers. But there are very few things that have been proven to have a cause-and-effect relationship.

– Penn State Milton S. Hershey Medical Center

Epigenetic Breakthrough: A First of Its Kind Tool to Study the Histone Code

UNC scientists have created a new research tool, based on the fruit fly, to help crack the histone code. This research tool can be used to better understand the function of histone proteins, which play critical roles in the regulation of gene expression in animals and plants.

 • Image(s) embedded • 

Developmental Cell

– University of North Carolina School of Medicine

Researcher Improves Cancer Detection with Image Analysis

Bin Zheng, OU electrical and computer engineering professor and Oklahoma Tobacco Settlement Endowment Trust Cancer Research Scholar, and his research team have developed image processing algorithms to generate quantitative image markers by analyzing multiple digital X-ray images and building statistical data learning-based prediction models. The goal is to develop a new quantitative image analysis method that better predicts cancer risk or cancer prognosis, which ultimately leads to help establish more effective personalized cancer screening and treatment strategies.

– University of Oklahoma, College of Engineering

Policy and Public Affairs

CMS Oncology Care Model Names NCCN Guidelines as High-Quality Care and Evidence-Based Recommendations

Centers for Medicare & Medicaid Services encourages concordance to NCCN Guidelines for Medicare patients in order to achieve better care, smarter spending, and healthier people.

– National Comprehensive Cancer Network® (NCCN®)

Announcements

Memorial Sloan Kettering Debuts New Mobile Application for Patients

Memorial Sloan Kettering Cancer Center (MSK) has debuted MyMSK, a new mobile application. The app, compatible with iPad, iPhone, and all iOS devices, allows MSK patients to quickly and easily access their lab and radiology results, view their upcoming appointments, record their medications and symptoms in online diaries, communicate with their healthcare team, and more.

– Memorial Sloan Kettering Cancer Center

NYU Langone Medical Center, Technion-Israel Institute of Technology to Forge Groundbreaking Partnership in Cancer Research

A major gift from philanthropists Laura and Isaac Perlmutter will fund two major, joint endeavors between NYU Langone Medical Center and Technion-Israel Institute of Technology to advance cancer research.

 • Image(s) embedded • 

– NYU Langone Medical Center

A California Pediatric Medical Facility Commits $50 Million to Support the Use of Genome Sequencing to Find Cures and Treatments for Young Patients

Children’s Hospital Los Angeles announced today that it will make an institutional commitment of $50 million to expand its Center for Personalized Medicine. This investment in leading-edge research and innovation will help unlock the human genome’s potential with the goal of making diagnoses more effective, therapies more targeted and health care more personalized for children. The Children’s Hospital Los Angeles Board of Trustees recently approved the investment in the Center, to be disbursed over the next five years. The institution will seek an additional $50 million in philanthropic funding from the community to support the translation of research outcomes in the lab into bedside care for infants, children and adolescents.

 • Image(s) embedded • 

– Childrens Hospital Los Angeles

UT Southwestern Receives Key National Cancer Institute Funding to Plan First U.S. Center for Heavy Ion Radiation Therapy Research

UT Southwestern Medical Center is leading a Texas consortium of researchers to establish the country’s first National Center for Heavy Ion Radiation Therapy that could provide clinical care and research using heavy particles for innovative new cancer treatments.

 • Image(s) embedded • 

– UT Southwestern Medical Center

Penn Orphan Disease Center Announces First Grant Recipients from Million Dollar Bike Ride

The Orphan Disease Center at the Perelman School of Medicine at the University of Pennsylvania, has awarded its inaugural grants funded by proceeds from the 2014 Million Dollar Bike Ride. Thirteen institutions – from academia in the US, Canada, Germany, and Australia – received grants ranging from $35,000 to $60,000 from funds raised by 13 disease-specific cycling teams.

 • Image(s) embedded • 

– Perelman School of Medicine at the University of Pennsylvania

University of Mississippi is AACI's Newest Member

The University of Mississippi Medical Center (UMMC) Cancer Institute, in Jackson, MS, has joined the Association of American Cancer Institutes.

 • Image(s) embedded • 

– Association of American Cancer Institutes (AACI)

Higher Education Events

Art Show Features Stunning Pieces from Contemporary Artists and Mother Nature

The goal of the “Art of Systems Biology and Nanoscience” annual event in Santa Fe is to share stunning scientific images of nature with the public.

– University of New Mexico Cancer Center

Tips

Forget your Newswise username/password?
Click "forgot my username/forgot my password" here, or go to our homepage and click "Login" on the top right.

Just a reminder, your password is case sensitive.

Changing your email address(es)? Update your profile by logging in and clicking "My User Profile" at the top right of the page.

Going on vacation? You can hold delivery of your Newswise wire subscriptions by logging in and clicking "My Account" at the top right of the page. Click on the "Subscriptions" tab to enter start and stop dates.

subscribe/unsubscribe :: edit my preferences
© 2015 Newswise, Inc. All Rights Reserved. | 215 E. 5th St. SW, Charlottesville VA 22903 | 434-296-9417 | Contact Us